Clinical trial information: NCT02963493Altres ajuts: Oncopeptides A

Alegre, Adrian

Anderson, Kenneth C.

Bakker, Nicolaas A.

Bladé, Joan

Byrne, Catriona

Cavo, Michele

Harmenberg, Johan

Hassoun, Hani

Hiemenz, John W.

Larocca, Alessandra

Laubach, Jacob P.

Leleu, Xavier

Maisel, Christopher

Mateos, M. V

Mazumder, Amitabha

Moreb, Jan S.

Nadeem, Omar

Oriol, Albert

Paner, Agne

Raptis, Anastasios

Richardson, Paul G.

Rodriguez-Otero, Paula

Thuresson, Marcus

Thuresson, Sara

Touzeau, Cyrille

English

PubMed

Bladé Creixenti, Juan

Diposit Digital de Documents de la UAB

Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma

International audiencePURPOSE Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor cells. The phase II HORIZON trial evaluated the efficacy of melflufen plus dexamethasone in relapsed and refractory multiple myeloma (RRMM), a population with an important unmet medical need. PATIENTS AND METHODS Patients with RRMM refractory to pomalidomide and/or an anti-CD38 monoclonal antibody received melflufen 40 mg intravenously on day 1 of each 28-day cycle plus once weekly oral dexamethasone at a dose of 40 mg (20 mg in patients older than 75 years). The primary end point was overall response rate (partial response or better) assessed by the investigator and confirmed by independent review. Secondary end points included duration of response, progression-free survival, overall survival, and safety. The primary analysis is complete with long-term follow-up ongoing. RESULTS Of 157 patients (median age 65 years; median five prior lines of therapy) enrolled and treated, 119 patients (76%) had triple-class-refractory disease, 55 (35%) had extramedullary disease, and 92 (59%) were refractory to previous alkylator therapy. The overall response rate was 29% in the all-treated population, with 26% in the triple-class-refractory population. In the all-treated population, median duration of response was 5.5 months, median progression-free survival was 4.2 months, and median overall survival was 11.6 months at a median follow-up of 14 months. Grade $ 3 treatment-emergent adverse events occurred in 96% of patients, most commonly neutropenia (79%), thrombocytopenia (76%), and anemia (43%). Pneumonia (10%) was the most common grade 3/4 nonhematologic event. Thrombocytopenia and bleeding (both grade 3/4 but fully reversible) occurred concomitantly in four patients. GI events, reported in 97 patients (62%), were predominantly grade 1/2 (93%); none were grade 4. CONCLUSION Melflufen plus dexamethasone showed clinically meaningful efficacy and a manageable safety profile in patients with heavily pretreated RRMM, including those with triple-class-refractory and extramedullary disease

Richardson, Paul, G

Hiemenz, John, W

Alegre, Adrián

Moreb, Jan, S

Anderson, Kenneth, C

Laubach, Jacob, P

Bakker, Nicolaas, A

Mateos, Victoria

HAL-Inserm

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma

Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma

Abstract

Similar works

Full text

Available Versions

Diposit Digital de Documents de la UAB

HAL-Inserm

Institutional Research Information System University of Turin

HAL-Univ-Nantes

Hal-Diderot